Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant vs Standard Endocrine Therapy in ER+/HER2- Early Breast Cancer
NCT06492616Phase 3Active, not recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Sep 2024
- Primary completion
- Aug 2029
- Modality
- Molecular Glues
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Elacestrant with Standard of Care (SoC) Endocrine Therapy (2 arms). Primary endpoint: Invasive Breast Cancer-Free Survival at 5 years. Started Sep 2024; status: active, not recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06492616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492616.